This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Specialty Control Plasma Market

Market Insights on Specialty Control Plasma covering sales outlook, demand forecast & up-to-date key trends

Specialty Control Plasma Market : Global Industry Analysis 2016 - 2020 and Opportunity Assessment 2021 - 2031

Specialty Control Plasma Market Overview

According to the latest research by FMI, Specialty Control Plasma is set to witness a 10.6% growth during the year 2021-2031. The specialty control plasma has gained significant traction by their application in the treatment of a range of conditions such as cardiac insufficiency, immune deficiency, hemorrhages, neurological conditions and infectious diseases. Additionally, specialty control plasma are used by clinical labs for assays to diagnose coagulation disorders such as hemophilia.

The advancement in the process of blood therapeutics and the key application of specialty control plasma in rheumatology, neurology, oncology, immunology, hematology and transplant have proven to be vital in patient care.   

What is Driving Demand for Specialty Control Plasma?

The specialty control plasma demand is driven by the rising instances of need of diagnostics for various coagulation disorders. The rising incidence of various autoimmune disorders, such as hemophilia and the growing role of the plasma and its derivative products in the diagnosis as well as treatment of the disorders has significantly acted as a catalyst to the specialty control plasma demand.

In addition, the growing awareness about specialized plasma products and their uptake, especially in the developed economies has added traction to the demand of specialty control plasma. Furthermore, special insurance aid policies by various bodies like the National Hemophilia Foundation, is expected to aid in the development of specialty control plasma.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which Factors are Likely to Augment Growth of Specialty Control Plasma Adoption?

Factors likely to augment the growth of specialty control plasma are the advancements in the specialized plasma-derived products and the plasma fractionation process. The rising geriatric population around the world and the prevalence of infectious diseases is also likely to act as a propelling factor for the specialty control plasma adoption for treatment and patient care.

Apart from this, the rising reported misdiagnosed conditions such as coagulation disorders is set to push the uptake of specialty control plasma for a significantly accurate diagnosis or detection. The advancements in biomedical technologies and detection assays as well as the growing awareness in terms of detection of immunological disorders is set to supplement the growth of specialty control plasma.

US and Canada Specialty Control Plasma Outlook

The specialty control plasma value is expected to experience a profitable growth in the region of North America over the forecast period. The current stance of this region is dominating globally in terms of development and manufacture of specialty control plasma.

The largest player in US and Canada, Precision Biologics, recently launched CRYOcheck for diagnosis of hemophilia A. Therefore, the growth of specialty control plasma in the region of North America is fueled by the rise in expenditure by various biotechnology companies as well as rising rate of improved healthcare structure.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Europe Demand Outlook for Specialty Control Plasma

The Europe specialty control plasma market is set to become the most lucrative segment over the forecast period owing to the high incidence of chronic diseases and the recognition and visibility of rare diseases as defined by the European Commission.

About 5000 – 8000 rare diseases are prevalent and affect almost 6-8% of the European population. The increasing fund allocation for such rare disorders has led to the advancement of specialty control plasma techniques for diagnosis as well as treatment or management of such disorders.

Who are the Key Manufacturers and Suppliers of Specialty Control Plasma?

The key companies dealing with specialty control plasma are

  • Precision BioLogic Incorporated
  • Baxter BioScience
  • Grifols S.A.
  • Shire Plc.
  • VitroPharma
  • Kedrion S.p.A.
  • China Biologic Products (Shandong Taibang)
  • Biotest AG
  • Sanquin
  • Talecris Biotherapeutics
  • SK Plasma Co.
  • CSL Ltd.
  • Octapharma AG
  • Cerus Corp.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Key Segments

By Type:

  • Factor VIII Concentrate
  • Factor IX Concentrate
  • Immunoglobulins
  • Others

By Application:

  • Coagulation disorders
    • Hemophilia
    • Von Willebrand disease
    • Other clotting disorders
  • Immunodeficiency diseases
  • Hypogammaglobulinemia

By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Clinics
  • Others

By Region:

  • North America
    • US
    • Canada
  • Latin America
    • Brazil
    • Mexico
  • Europe
    • Germany
    • Italy
    • France
    • U.K.
    • Spain
    • BENELUX
    • Russia
  • South Asia
    • India
    • Thailand
    • Malaysia
    • Indonesia
    • Rest of South Asia
  • East Asia
  • China
  • Japan
  • South Korea
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Turkey
Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Specialty Control Plasma Market